Table 1 Clinical characteristic of patients with rheumatoid arthritis
From: Suppressed diversity of survivin splicing in active rheumatoid arthritis
Cohort (n = 67) | Rituximab-treated group (n = 23) | |
|---|---|---|
Age (years) | 56.6 (24–79) | 59.4 (29–79) |
Female/male | 65/2 | 21/2 |
Disease duration (years) | 10.2 (1–40) | 13.1 (2–33) |
RF positive (%) | 83.6 | 96.0 |
ACPA positive (%) | 71.7 | 83.0 |
DAS28 | 3.86 (1.38–6.77) | 5.89 (4.6–6.8) |
Methotrexate (n) | 55 (82.1 %) | 18 (78.3 %) |
Dose (mg/week) | 18.2 (7.5–25) | 18.0 (10–25) |
Anti-TNFα | 10 (14.9 %) | 0 |
Rituximab | 13 (19.4 %) | 9 (39.1 %) |
Anti-IL-6R | 2 (3.0 %) | 0 |
CTLA4 | 1 (1.5 %) | 0 |
Serum survivin (ng/ml) | 18.5 (0.02–306.21) | 2.07(0.10–14.9) |